Introgen Therapeutics (INGNQ) 8-K Introgen Therapeutics Reports Fourth Quarter 2005 Financial Results

Exhibit 99.1

FOR IMMEDIATE RELEASE

Introgen Therapeutics Reports Fourth Quarter 2005 Financial Results

Results in Line with Expectations

AUSTIN, TX, March 15, 2006– Introgen Therapeutics, Inc. (NASDAQ: INGN) announced today its results for the quarter and year ended December 31, 2005, reporting progress during the period in its research and development and clinical trial programs.

During the quarter ended December 31, 2005 Introgen used cash, cash equivalents and short-term investments of $5.1 million to conduct its operations. Introgen’s cash, cash equivalents, marketable securities and short-term investments were $36.0 million at December 31, 2005. Revenue was $624,000 for the quarter ended December 31, 2005, compared to revenue of $398,000 for the quarter ended September 30, 2005 and $1.2 million for the quarter ended December 31, 2004. Operating expense was $7.7 million for the quarter ended December 31, 2005, compared to $6.7 million for the quarter ended September 30, 2005 and $5.8 million for the quarter ended December 31, 2004.

Introgen reported a net loss of $6.7 million, or $0.19 per share, for the quarter ended December 31, 2005. These results compare to a net loss of $6.1 million, or $0.18 per share, for the previous quarter ended September 30, 2005 and a net loss of $4.4 million, or $0.16 per share, for the comparable quarter ended December 31, 2004.

For the year ended December 31, 2005, Introgen reported a net loss of $26.1 million, or $0.80 per share, compared to a net loss of $24.4 million, or $0.91 per share, for the year ended December 31, 2004. Revenue for the year ended December 31, 2005 was $1.9 million, compared to revenue of $1.8 million for the year ended December 31, 2004. Operating expense was $29.2 million for the year ended December 31, 2005 compared to $27.1 million for the year ended December 31, 2004.

Quarterly Conference Call

Introgen has scheduled a conference call to discuss the financial results at 4:30 p.m. Eastern Standard Time today. Interested parties can access a live Internet broadcast at www.introgen.com. The call may also be accessed by dialing 1-877-616-4476 or 1-706-679- 7372. For those unable to listen to the broadcast the call will be archived at Introgen’s website in the Investor Relations section.

Introgen Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted molecular therapies for the treatment of cancer and other diseases. Introgen is developing molecular therapeutics, immunotherapies, vaccines and nano-particle tumor suppressor therapies to treat a wide range of cancers using tumor suppressors, cytokines and genes.

Introgen maintains integrated research, development, manufacturing, clinical and regulatory departments and operates multiple manufacturing facilities including a commercial scale cGMP manufacturing facility.

Statements in this release that are not strictly historical may be “forward-looking” statements, including those relating to Introgen’s future success with its clinical development program for treatment of cancer or other diseases and Introgen’s financial performance. The actual results may differ from those described in this release due to risks and uncertainties that exist in Introgen’s operations and business environment, including Introgen’s stage of product development and the limited experience in the development of gene-based drugs in general, dependence upon proprietary technology and the current competitive environment, history of operating losses and accumulated deficits, reliance on collaborative relationships, and uncertainties related to clinical trials, the safety and efficacy of Introgen’s product candidates, the ability to obtain the appropriate regulatory approvals, Introgen’s patent protection and market acceptance, as well as other risks detailed from time to time in Introgen’s filings with the Securities and Exchange Commission including its filings on Form 10-K and Form 10-Q. Introgen undertakes no obligation to publicly release the results of any revisions to any forward-looking statements that reflect events or circumstances arising after the date hereof.

###

Editor’s Note: For more information on Introgen Therapeutics, or for a menu of archived press releases, please visit Introgen’s Website atwww.introgen.com.

Contact:
Introgen Therapeutics, Inc.
C. Channing Burke
(512) 708 9310 Ext. 322
Email: c.burke@introgen.com

INTROGEN THERAPEUTICS, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEET

	DECEMBER 31,		DECEMBER 31,
	2005		2004
	(Thousands)
CASH, CASH EQUIVALENTS, SHORT-TERM INVESTMENTS AND MARKETABLE SECURITIES		36,014		38,180
OTHER CURRENT ASSETS		297		659
PROPERTY AND EQUIPMENT, NET		6,181		7,277
GRANT RIGHTS ACQUIRED		163		1,582
OTHER ASSETS		326		359
TOTAL ASSETS	$	42,981	$	48,057
ACCOUNTS PAYABLE, ACCRUALS AND OTHER CURRENT LIABILITIES	$	6,782	$	6,858
NOTES PAYABLE, NET OF CURRENT PORTION		7,784		7,901
OTHER LONG TERM LIABILITIES		1,404		1,132
TOTAL LIABILITIES		15,970		15,891
TOTAL STOCKHOLDERS’ EQUITY		27,011		32,166
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$	42,981	$	48,057

INTROGEN THERAPEUTICS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENT OF OPERATIONS
(Unaudited)

	THREE MONTHS ENDED						YEAR ENDED
	DECEMBER 31,						DECEMBER 31,
	2005			2004			2005			2004
	(Unaudited)			(Unaudited)
	(Thousands except per share information.)
CONTRACT SERVICES, GRANT AND OTHER REVENUE	$	624		$	1,217		$	1,867		$	1,808
OPERATING EXPENSE:
RESEARCH AND DEVELOPMENT		5,371			4,497			21,400			20,474
GENERAL AND ADMINISTRATIVE		2,361			1,296			7,834			6,597
TOTAL OPERATING EXPENSE		7,732			5,793			29,234			27,071
LOSS FROM OPERATIONS		(7,108	)		(4,576	)		(27,367	)		(25,263	)
INTEREST INCOME, INTEREST EXPENSE AND OTHER INCOME, NET		361			208			1,264			876
NET (LOSS)	($	6,747	)	($	4,368	)	($	26,103	)	($	24,387	)
NET LOSS PER SHARE, BASIC AND DILUTED	($	0.19	)	($	0.16	)	($	0.80	)	($	0.91	)
SHARES USED IN COMPUTING BASIC AND DILUTED NET LOSS PER SHARE		35,742			27,886			32,780			26,943